Stella Therapeutics, Inc. logo

Stella Therapeutics, Inc.

Stella Therapeutics is developing novel brain penetrating small molecules with unique mechanism of action, which initially inhibits the migration and proliferation of tumor cells, and then selectively kills cancer cells through apoptosis.

Stella Therapeutics (University of Washington spin out), obtained an exclusive license to novel Glioblastoma Multiforme therapy from the University of Washington and University of Montana.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://stellatherapeutics.com
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
720 Broadway Ste 411, WA 98122-4302
Seattle
United States
Email
Contact Number
+1 206-726-1247

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/stella-therapeutics-inc” connections=”true” suffix=””]

Stellas noble drug entities (ST drugs) are based on the rational modification and optimization of the ?9-tetrahydrocannabinol, the bioactive active ingredient produced by the plant cannabis, which kills GBM cancer cells.

In Sep. 2013, Stella secured grant worth $250,000 USD from Life Sciences Discovery Fund (LSDF) to complete preclinical testing of its small-molecule against glioblastoma. Stella also received Ph I & Ph II SBIR grants from the NCI-NIH.